HALOZYME THERAPEUTICS INC (HALO) Fundamental Analysis & Valuation

NASDAQ:HALO • US40637H1095

Current stock price

68.41 USD
-1.16 (-1.67%)
At close:
68.41 USD
0 (0%)
After Hours:

This HALO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. HALO Profitability Analysis

1.1 Basic Checks

  • In the past year HALO was profitable.
  • HALO had a positive operating cash flow in the past year.
  • HALO had positive earnings in each of the past 5 years.
  • Each year in the past 5 years HALO had a positive operating cash flow.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

1.2 Ratios

  • HALO has a Return On Assets of 12.55%. This is amongst the best in the industry. HALO outperforms 94.19% of its industry peers.
  • The Return On Equity of HALO (649.18%) is better than 100.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 25.65%, HALO belongs to the top of the industry, outperforming 98.45% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for HALO is significantly below the industry average of 27.75%.
  • The 3 year average ROIC (20.76%) for HALO is below the current ROIC(25.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROIC 25.65%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • HALO has a better Profit Margin (22.69%) than 93.22% of its industry peers.
  • In the last couple of years the Profit Margin of HALO has declined.
  • The Operating Margin of HALO (58.45%) is better than 99.81% of its industry peers.
  • HALO's Operating Margin has improved in the last couple of years.
  • The Gross Margin of HALO (83.62%) is better than 86.63% of its industry peers.
  • In the last couple of years the Gross Margin of HALO has remained more or less at the same level.
Industry RankSector Rank
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. HALO Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
  • The number of shares outstanding for HALO has been reduced compared to 1 year ago.
  • The number of shares outstanding for HALO has been reduced compared to 5 years ago.
  • The debt/assets ratio for HALO is higher compared to a year ago.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • HALO has an Altman-Z score of 3.95. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • HALO's Altman-Z score of 3.95 is fine compared to the rest of the industry. HALO outperforms 70.16% of its industry peers.
  • HALO has a debt to FCF ratio of 6.00. This is a slightly negative value and a sign of low solvency as HALO would need 6.00 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 6.00, HALO belongs to the top of the industry, outperforming 90.89% of the companies in the same industry.
  • HALO has a Debt/Equity ratio of 43.89. This is a high value indicating a heavy dependency on external financing.
  • HALO has a Debt to Equity ratio of 43.89. This is amonst the worse of the industry: HALO underperforms 83.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Altman-Z 3.95
ROIC/WACC2.99
WACC8.58%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 4.66 indicates that HALO has no problem at all paying its short term obligations.
  • HALO has a Current ratio (4.66) which is in line with its industry peers.
  • HALO has a Quick Ratio of 3.66. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • HALO has a Quick ratio (3.66) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.66
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. HALO Growth Analysis

3.1 Past

  • HALO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.36%.
  • The Earnings Per Share has been growing by 35.63% on average over the past years. This is a very strong growth
  • The Revenue has grown by 37.55% in the past year. This is a very strong growth!
  • HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.16% yearly.
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.27% on average over the next years. This is quite good.
  • HALO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.11% yearly.
EPS Next Y97.97%
EPS Next 2Y55.93%
EPS Next 3Y36.6%
EPS Next 5Y16.27%
Revenue Next Year26.75%
Revenue Next 2Y19.45%
Revenue Next 3Y15.71%
Revenue Next 5Y5.11%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. HALO Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 16.56, the valuation of HALO can be described as correct.
  • HALO's Price/Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 94.77% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.95. HALO is valued slightly cheaper when compared to this.
  • A Price/Forward Earnings ratio of 8.37 indicates a reasonable valuation of HALO.
  • Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 98.26% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of HALO to the average of the S&P500 Index (38.68), we can say HALO is valued rather cheaply.
Industry RankSector Rank
PE 16.56
Fwd PE 8.37
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • 95.74% of the companies in the same industry are more expensive than HALO, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, HALO is valued cheaply inside the industry as 94.96% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 22.71
EV/EBITDA 11.32
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of HALO may justify a higher PE ratio.
  • A more expensive valuation may be justified as HALO's earnings are expected to grow with 36.60% in the coming years.
PEG (NY)0.17
PEG (5Y)0.46
EPS Next 2Y55.93%
EPS Next 3Y36.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HALO Dividend Analysis

5.1 Amount

  • HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HALO Fundamentals: All Metrics, Ratios and Statistics

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (4/21/2026, 4:30:01 PM)

After market: 68.41 0 (0%)

68.41

-1.16 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-12
Inst Owners107.43%
Inst Owner Change-0.1%
Ins Owners0.86%
Ins Owner Change0.92%
Market Cap8.10B
Revenue(TTM)1.40B
Net Income(TTM)316.89M
Analysts76
Price Target86.59 (26.58%)
Short Float %11.99%
Short Ratio7.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.57%
Min EPS beat(2)-110.7%
Max EPS beat(2)3.56%
EPS beat(4)3
Avg EPS beat(4)-18.27%
Min EPS beat(4)-110.7%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)-1.32%
EPS beat(12)9
Avg EPS beat(12)0.23%
EPS beat(16)12
Avg EPS beat(16)2.67%
Revenue beat(2)2
Avg Revenue beat(2)1.65%
Min Revenue beat(2)1.13%
Max Revenue beat(2)2.18%
Revenue beat(4)4
Avg Revenue beat(4)6.95%
Min Revenue beat(4)1.13%
Max Revenue beat(4)12.81%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.56%
PT rev (1m)0.46%
PT rev (3m)10.07%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)-13.3%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)0.32%
Revenue NQ rev (3m)-1.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.83%
Valuation
Industry RankSector Rank
PE 16.56
Fwd PE 8.37
P/S 5.8
P/FCF 22.71
P/OCF 12.44
P/B 166.03
P/tB N/A
EV/EBITDA 11.32
EPS(TTM)4.13
EY6.04%
EPS(NY)8.18
Fwd EY11.95%
FCF(TTM)3.01
FCFY4.4%
OCF(TTM)5.5
OCFY8.04%
SpS11.79
BVpS0.41
TBVpS-12.77
PEG (NY)0.17
PEG (5Y)0.46
Graham Number6.18777 (-90.95%)
Profitability
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROCE 34.76%
ROIC 25.65%
ROICexc 27.31%
ROICexgc 93.59%
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
FCFM 25.55%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
ROICexc(3y)25.83%
ROICexc(5y)35.19%
ROICexgc(3y)78.99%
ROICexgc(5y)74.81%
ROCE(3y)28.13%
ROCE(5y)25.85%
ROICexgc growth 3Y19.79%
ROICexgc growth 5YN/A
ROICexc growth 3Y19.91%
ROICexc growth 5YN/A
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Debt/EBITDA 2.37
Cap/Depr 334.74%
Cap/Sales 21.1%
Interest Coverage 71.42
Cash Conversion 72.05%
Profit Quality 112.6%
Current Ratio 4.66
Quick Ratio 3.66
Altman-Z 3.95
F-Score5
WACC8.58%
ROIC/WACC2.99
Cap/Depr(3y)121.97%
Cap/Depr(5y)85.12%
Cap/Sales(3y)8%
Cap/Sales(5y)5.01%
Profit Quality(3y)116.88%
Profit Quality(5y)108.21%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
EPS Next Y97.97%
EPS Next 2Y55.93%
EPS Next 3Y36.6%
EPS Next 5Y16.27%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%
Revenue Next Year26.75%
Revenue Next 2Y19.45%
Revenue Next 3Y15.71%
Revenue Next 5Y5.11%
EBIT growth 1Y48.02%
EBIT growth 3Y41.29%
EBIT growth 5Y41.42%
EBIT Next Year38.07%
EBIT Next 3Y22.25%
EBIT Next 5Y8.86%
FCF growth 1Y-23.82%
FCF growth 3Y14.89%
FCF growth 5Y46.43%
OCF growth 1Y36.01%
OCF growth 3Y39.48%
OCF growth 5Y63.66%

HALOZYME THERAPEUTICS INC / HALO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 7 / 10 to HALO.


Can you provide the valuation status for HALOZYME THERAPEUTICS INC?

ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.


What is the profitability of HALO stock?

HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.


What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 16.56 and the Price/Book (PB) ratio is 166.03.


What is the expected EPS growth for HALOZYME THERAPEUTICS INC (HALO) stock?

The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 97.97% in the next year.